Materias dentro de su búsqueda.
Mostrando 1,921 - 1,940 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.35s Limitar resultados
  1. 1921
    “…We show that 3 selectively targets bromodomain-containing protein 4 (BRD4) for degradation only in HER2 positive breast cancer cell lines, while sparing HER2 negative cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
  2. 1922
    “…PURPOSE: Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormone therapy (HT). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
  3. 1923
    “…Conflicting results have been reported regarding the prevalence of screen-detected human epidermal growth factor receptor 2 (HER2)-positive breast carcinomas and non-screen detected HER2-positive breast carcinomas. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers
  4. 1924
    “…Similarly, multi-locus signatures for the ER+/HER2- and AI cohorts were conserved in endocrine-resistant T47D cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer
  5. 1925
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Highly Porous MIL-100(Fe) for the Hydrogen Evolution Reaction (HER) in Acidic and Basic Media
  6. 1926
    “…HER2 mutations have emerged as oncogenic driver gene mutations in non-small cell lung cancer (NSCLC), which have not been described in detail like other driver gene mutations. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
  7. 1927
    “…BACKGROUND: Ubiquitin specific peptidase 8 (USP8) has been reported to induce the degradation of several receptor tyrosine kinases such as epidermal growth factor receptor (EGFR), among which human epidermal growth factor receptor-3 (HER-3) is one of them. However, the role and functional mechanisms of USP8 and HER-3 in gastric cancer (GC) remain unknown. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Down-Regulation of USP8 Suppresses HER-3 Positive Gastric Cancer Cells Proliferation
  8. 1928
    “…Tumors of pure mucinous carcinoma are typically positive for both estrogen receptor (ER) and progesterone receptor (PR), and they do not commonly overexpress human epidermal growth factor receptor 2 (HER2). However, when tumors have HER2 overexpression and are progesterone receptor negative, the prognosis is worse. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-positive pure mucinous breast carcinoma: A case report and literature review
  9. 1929
    “…We determined a cut-off value for NGS to categorize HER2 amplification status by using 151 HER2 non-amplified FFPE samples. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers
  10. 1930
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Author Correction: Her9/Hes4 is required for retinal photoreceptor development, maintenance, and survival
  11. 1931
    “…We highlight the complex situation when an elderly woman with urinary tract infection (UTI) and her daughter meet the highly qualified health care system. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Complicated versus complexity: when an old woman and her daughter meet the health care system
  12. 1932
    “…Interestingly, TrkA was significantly increased in tumours expressing the human epidermal growth factor receptor-2 (HER2), with expression in 49% of HER2-positive compared to 25% of HER2-negative tumours (p = 0.0027). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
  13. 1933
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
  14. 1934
    “…OBJECTIVE: To explore the relationship between the HER2 gene and PD-1/PD-L1 in gastric cancer and its significance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer
  15. 1935
    “…RESULTS: No significant difference was observed between the two HER2 antibodies. Of the 93 cases, 22.58% demonstrated at least focal and 1+ HER2 positivity. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial Antibodies
  16. 1936
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
  17. 1937
    “…Some studies have shown that pyrotinib, an ErbB receptor tyrosine kinase inhibitor, is effective against HER2(+) breast cancer. However, whether pyrotinib sensitizes 5-FU-resistant breast cancer cells to 5-FU is unknown. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2(+) Breast Cancer Cells to 5-Fluorouracil
  18. 1938
    “…Thus, we aimed to explore the cost-effectiveness of ribociclib for postmenopausal patients with HR-positive and HER2-negative ABC. METHODS: A comprehensive Markov model was developed to estimate the cost-effectiveness of ribociclib plus fulvestrant versus placebo plus fulvestrant as first-line treatment for HR-positive, HER2-negative ABC. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
  19. 1939
    “…Conclusions: overall, our results suggest that ANXA1 may be a useful prognostic marker in HER-2+ patients. Additionally, its ability to discriminate between HER-2+ (non-luminal) and luminal B-like (HER-2+) patients might assist in patient stratification regarding treatment strategy.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer
  20. 1940
    “…Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Herramientas de búsqueda: RSS